Hodgkin Lymphoma CA209-812

The purpose of this study is to determine whether an investigational immuno-therapy combination, nivolumab with Brentuximab vedotin compared to Brentuximab vedotin alone is safe and effective in the treatment of relapsed and refractory Classical Hodgkin Lymphoma. The participants of this trial will comprise of patients who have relapsed or did not respond to treatment and are not eligible for stem cell transplant

Eligibility Criteria:

  1. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
  2. Participants must have a pathologic diagnosis of classical Hodgkin lymphoma (cHL) who are relapsed or refractory with one of the following:
    1. Autologous stem cell transplant (ASCT) ineligible patients
    2. Patients after failure of ASCT
  2. Must have at least one lesion that is > 15 mm (1.5 cm) in the longest diameter and avid by Fluoro Deoxy Glucose (FDG) Positron Emission Tomography (PET) scan

This study is for patients age 18 and older.

Available at: Hospital of Central Connecticut

Cancer Clinical Research Office